JAGSNPHARMNSEJagsonpal Pharmaceuticals Limited· PharmaceuticalsMinimalNeutral
Announced Wed, 29 Apr · 16:36 IST

Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+3.1%1-day move
₹208.50
prior close
₹209.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.2-1.3-1.4-0.2+3.1+0.7+0.7+2.8+4.2+1.7+0.2-3.1+15.1
Up moveDown movePending
AI summary

Jagsonpal Pharmaceuticals has informed the stock exchanges about publishing extracts of its audited financial results for Q4 and the financial year ended March 31, 2026, in Business Standard (English and Hindi) newspapers on April 29, 2026. This filing is made pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates newspaper publication of quarterly and annual financial results. The newspaper advertisement headline appears to promote shareholder value, indicating 'Jagsonpal Strengthens Shareholder Wealth' and 'Declares 200% Dividend' for FY 2026. The actual detailed financial numbers are not included in this filing since it only references the newspaper advertisement.

Likely market impact

This is a routine regulatory compliance filing confirming that the company's audited financial results for FY 2026 have been made public through newspaper publication. The headline suggesting a 200% dividend declaration indicates positive shareholder returns for the financial year, which is typically viewed favorably by investors.